Health Care & Life Sciences » Pharmaceuticals | Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
32,027.50
36,901.90
33,519.10
33,025.60
41,150.10
40,741.80
Cost of Goods Sold (COGS) incl. D&A
6,741.30
7,042.70
7,215.00
8,355.60
10,018.30
10,360.80
Gross Income
25,286.20
29,859.10
26,304.10
24,670.00
31,131.80
30,381
SG&A Expense
29,087.50
26,300.30
25,492.50
26,103.10
35,213.10
37,731.70
EBIT
3,801.30
3,558.80
811.60
1,433.10
4,081.40
7,350.80
Unusual Expense
-
-
300.00
-
-
40
Non Operating Income/Expense
-
67.10
-
-
-
-
Interest Expense
103.40
-
73.90
106.40
92.90
195.80
Pretax Income
3,674.50
3,743.20
1,246.90
1,334.90
3,874.90
7,022.10
Income Tax
1,523.10
1,380.70
575.80
330.90
4,174.90
16.60
Consolidated Net Income
2,151.40
2,362.50
671.10
1,003.90
8,049.80
7,038.80
Net Income
2,104.60
2,423.70
731.40
944.70
7,978.60
6,963.10
Net Income After Extraordinaries
2,104.60
2,423.70
731.40
944.70
7,978.60
6,963.10
Net Income Available to Common
2,104.60
2,423.70
731.40
944.70
7,978.60
6,963.10
EPS (Basic)
0.11
0.14
0.04
0.06
0.50
0.45
Basic Shares Outstanding
18,333.00
17,617.80
16,716.00
16,236.50
15,911.60
15,614.10
EPS (Diluted)
0.11
0.14
0.04
0.06
0.50
0.45
Diluted Shares Outstanding
18,333.00
17,899.60
17,094.80
16,236.50
15,911.60
15,614.10
EBITDA
2,499.50
5,548.40
3,058.40
963.80
1,433.60
4,368.10
Non-Operating Interest Income
230.30
251.40
209.20
204.70
299.30
564.50
Minority Interest Expense
46.80
61.30
60.20
59.30
71.20
75.70

About Cumberland Pharmaceuticals

View Profile
Address
2525 West End Avenue
Nashville Tennessee 37203
United States
Employees -
Website http://www.cumberlandpharma.com
Updated 07/08/2019
Cumberland Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of brands for the hospital acute care, gastroenterology, and oncology. Its product brands include acetadote, caldolor, kristalose, hepatoren, omeclamox, vaprisol, boxaban, vasculan, ethyol, portaban, and totect. The company was founded by A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.